Bipolar I Disorder Clinical Trial
Official title:
Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study
The primary aim of this project is to understand whether it is possible to reduce medical risk factors in adults with bipolar disorder and, in doing so, to improve psychiatric and functional outcomes. We will examine the role of behavioral risk factors and presumed behavioral mediators and moderators of health risk in individuals suffering from bipolar I disorder. The investigators will employ an innovative behavioral intervention with guideline based psychiatric care ( Integrated Risk Reduction Intervention - IRRI) in order to target modifiable medical risk factors.
IRRI is aimed at improving sleep/wake and social rhythm disturbance and achieving modest weight reduction by increasing physical activity and improving nutrition and dietary habits, while at the same time providing optimal psychiatric care and medical monitoring. This will allow us to investigate the role that improvements in sleep/wake and social rhythm regularity, diet, and physical activity have in improving psychiatric and functional outcomes. In order to examine another set or possible pathways (i.e., that it is the amelioration or psychiatric symptoms that leads to the improvements in physical health), we will contrast outcomes of subjects receiving IRRI with those of subjects receiving psychiatric care with medical monitoring (PCMM), which incorporates the same optimal psychiatric care plus monitoring of medical conditions. These aims will be achieved in a 24-month randomized treatment trial of 144 adult subjects with bipolar I disorder. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
| Withdrawn |
NCT01495156 -
Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania
|
Phase 4 | |
| Completed |
NCT00982020 -
Study in Adolescents With Schizophrenia or Bipolar Disorder
|
Phase 4 | |
| Completed |
NCT00177463 -
L-Carnosine for Bipolar I Disorder
|
N/A | |
| Completed |
NCT03257865 -
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
|
Phase 3 | |
| Completed |
NCT03259555 -
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
|
Phase 3 | |
| Not yet recruiting |
NCT06433635 -
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
|
Phase 4 | |
| Completed |
NCT04127058 -
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
|
Phase 1 | |
| Recruiting |
NCT05977023 -
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
|
Phase 2 | |
| Recruiting |
NCT05340686 -
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
|
N/A | |
| Completed |
NCT03287869 -
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
|
Phase 3 | |
| Enrolling by invitation |
NCT04987229 -
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT00761761 -
Sensoril(Ashwaganhda)for Bipolar Disorder
|
Phase 3 | |
| Completed |
NCT00232414 -
A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder
|
Phase 3 | |
| Completed |
NCT03292848 -
Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders
|
Phase 1 | |
| Active, not recruiting |
NCT04561622 -
Emotional Proactive Processing in Bipolar Disorder
|
||
| Recruiting |
NCT03943537 -
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
|
Phase 2 | |
| Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
| Completed |
NCT00958633 -
Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.
|
Phase 3 |